Literature DB >> 24157925

Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy.

M Opyrchal1, C Allen, P Msaouel, I Iankov, E Galanis.   

Abstract

RhoA and its downstream effector Rho-associated coiled-coil-forming kinase (ROCK) are known regulators of the formation of actin cytoskeleton in cells. Actin cytoskeleton is involved in paramyxovirus infection; we, therefore, examined the effect of ROCK inhibition on measles virus (MV) cytopathic effect and replication. Treatment with the ROCK inhibitor, Y27632, significantly increased syncytia size in tumor cell lines following MV infection, associated with cytoskeleton disruption as demonstrated by actin staining. Treatment of prostate cancer, breast cancer and glioblastoma tumor cell lines with Y27632 following MV infection resulted in increased cytopathic effect, as assessed by trypan blue exclusion assays. In addition, there was a significant increase in viral proliferation by at least one log or more as tested in one-step viral growth curves. Increased viral replication was also observed in athymic nude mice bearing MDA-MB-231 xenografts following combination treatment with MV and Y27632. In summary, inhibition of the ROCK kinase by Y27632 enhanced the oncolytic effect of MV and viral proliferation; this approach merits further translational investigation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24157925      PMCID: PMC3903406          DOI: 10.1038/cgt.2013.58

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  63 in total

1.  The actin cytoskeleton inhibits pore expansion during PIV5 fusion protein-promoted cell-cell fusion.

Authors:  Mark A Wurth; Rachel M Schowalter; Everett Clinton Smith; Carole L Moncman; Rebecca Ellis Dutch; Richard O McCann
Journal:  Virology       Date:  2010-08-15       Impact factor: 3.616

2.  Cooperativity of actin and microtubule elements during replication of respiratory syncytial virus.

Authors:  Nicole L Kallewaard; Amber L Bowen; James E Crowe
Journal:  Virology       Date:  2005-01-05       Impact factor: 3.616

3.  Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases.

Authors:  T Ishizaki; M Uehata; I Tamechika; J Keel; K Nonomura; M Maekawa; S Narumiya
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

4.  Genomic analysis of metastasis reveals an essential role for RhoC.

Authors:  E A Clark; T R Golub; E S Lander; R O Hynes
Journal:  Nature       Date:  2000-08-03       Impact factor: 49.962

5.  Rho GTPases are over-expressed in human tumors.

Authors:  G Fritz; I Just; B Kaina
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

6.  Involvement of small GTPases Rho and Rac in the invasion of rat ascites hepatoma cells.

Authors:  F Imamura; M Mukai; M Ayaki; K Takemura; T Horai; K Shinkai; H Nakamura; H Akedo
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

7.  Treatment of medulloblastoma with a modified measles virus.

Authors:  Adam W Studebaker; Cole R Kreofsky; Christopher R Pierson; Stephen J Russell; Evanthia Galanis; Corey Raffel
Journal:  Neuro Oncol       Date:  2010-05-21       Impact factor: 12.300

8.  RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.

Authors:  Ronil A Patel; Kara D Forinash; Roberta Pireddu; Ying Sun; Nan Sun; Mathew P Martin; Ernst Schönbrunn; Nicholas J Lawrence; Saïd M Sebti
Journal:  Cancer Res       Date:  2012-07-30       Impact factor: 12.701

9.  Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

Authors:  David Dingli; Kah-Whye Peng; Mary E Harvey; Philip R Greipp; Michael K O'Connor; Roberto Cattaneo; John C Morris; Stephen J Russell
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

10.  Cooperative anti-invasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activity.

Authors:  Marion de Toledo; Christelle Anguille; Laureline Roger; Pierre Roux; Gilles Gadea
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

View more
  6 in total

Review 1.  Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Angela Dispenzieri; Kah Whye Peng; Mark J Federspiel; Stephen J Russell; Evanthia Galanis
Journal:  Curr Cancer Drug Targets       Date:  2018       Impact factor: 3.428

Review 2.  Potential and clinical translation of oncolytic measles viruses.

Authors:  Steven Robinson; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2017-03       Impact factor: 4.388

Review 3.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

Review 4.  Engineering and combining oncolytic measles virus for cancer therapy.

Authors:  Mathias F Leber; Serge Neault; Elise Jirovec; Russell Barkley; Aida Said; John C Bell; Guy Ungerechts
Journal:  Cytokine Growth Factor Rev       Date:  2020-07-03       Impact factor: 7.638

Review 5.  Promising oncolytic agents for metastatic breast cancer treatment.

Authors:  James J Cody; Douglas R Hurst
Journal:  Oncolytic Virother       Date:  2015-06-03

6.  Live Attenuated Measles Virus Vaccine Expressing Helicobacter pylori Heat Shock Protein A.

Authors:  Ianko D Iankov; Cheyne Kurokawa; Kimberly Viker; Steven I Robinson; Arun Ammayappan; Eleni Panagioti; Mark J Federspiel; Evanthia Galanis
Journal:  Mol Ther Oncolytics       Date:  2020-09-23       Impact factor: 7.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.